BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.

Gilli, Stefanie; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Rauch, Daniel; Pabst, Thomas (2017). BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of hematology, 96(3), pp. 421-429. Springer 10.1007/s00277-016-2900-y

[img] Text
BM_GMB_BeEAM conditioning with bendamustine-replacing BCNU .pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (388kB) | Request a copy

BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (>20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara and Pabst, Thomas

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

0939-5555

Publisher:

Springer

Language:

English

Submitter:

Katrin Kölliker-Schütz

Date Deposited:

06 Feb 2017 15:04

Last Modified:

12 Feb 2018 16:00

Publisher DOI:

10.1007/s00277-016-2900-y

PubMed ID:

28011985

Uncontrolled Keywords:

Autologous; BCNU; BeEAM; Beam; Bendamustine; Chemotherapy; High dose; Lymphoma; Prognosis; Stem cell; Survival; Transplantation / Baerlocher Gabriela M. / Mansouri Taleghani Behrouz

BORIS DOI:

10.7892/boris.93689

URI:

https://boris.unibe.ch/id/eprint/93689

Actions (login required)

Edit item Edit item
Provide Feedback